IONSIONIS PHARMACEUTICALS INC

Nasdaq ionispharma.com


$ 47.65 $ -2.22 (-4.45 %)    

Friday, 30-Aug-2024 15:59:55 EDT
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 47.68
$ 47.68 x 200
-- x --
-- - --
$ 35.95 - $ 54.44
2,110,450
na
6.97B
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-21-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-01-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 02-28-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 02-26-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-05-2015 03-31-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-neutral-on-ionis-pharmaceuticals-raises-price-target-to-55

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and raises the price target from ...

 guggenheim-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-70

Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target...

 goldman-sachs-maintains-sell-on-ionis-pharmaceuticals-raises-price-target-to-37

Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Sell and raises the price target ...

 barclays-maintains-equal-weight-on-ionis-pharmaceuticals-raises-price-target-to-51

Barclays analyst Gena Wang maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight and raises the price target fro...

 needham-reiterates-buy-on-ionis-pharmaceuticals-maintains-60-price-target

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

 bmo-capital-downgrades-ionis-pharmaceuticals-to-market-perform-lowers-price-target-to-60

BMO Capital analyst Kostas Biliouris downgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Outperform to Market Perform and lo...

Core News & Articles

Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therape...

 leerink-partners-upgrades-ionis-pharmaceuticals-to-outperform-raises-price-target-to-62

Leerink Partners analyst Mani Foroohar upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and ra...

 td-cowen-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-59

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $54 ...

 b-of-a-securities-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-68

B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price targe...

 needham-reiterates-buy-on-ionis-pharmaceuticals-maintains-60-price-target

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.

 ionis-rare-development-disorder-drug-candidate-could-be-differentiated-from-peer-ultragenyx-analyst

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinic...

 ionis-pharmaceuticals-announces-phase-12-results-for-angelman-syndrome-treatment

 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive results from the completed multiple ascending dose (MAD) po...

 b-of-a-securities-maintains-buy-on-ionis-pharmaceuticals-raises-price-target-to-67

B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price targe...

 jefferies-upgrades-ionis-pharmaceuticals-to-buy-raises-price-target-to-75

Jefferies analyst Akash Tewari upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Buy and raises the price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION